Aardvark Therapeutics, Inc. Common Stock (AARD) Stock: Price, Forecast & Analyst Target
Aardvark Therapeutics, Inc. Common Stock (AARD) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.9226 (-7.74%), as of the Nov 20, 2026 trading session; market cap $20.2M.
Educational signal · not a buy or sell recommendation · How to read this
Aardvark Therapeutics, Inc. Common Stock · AARD · NASDAQ
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for metabolic diseases.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Aardvark Therapeutics, Inc. Common Stock (AARD)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a strained balance sheet and stalling growth, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Strained; Valuation: Fair; Growth Durability: Shrinking; Momentum: Falling.
- EPS beat 0 of the last 4 reports
- Altman Z -4.31 · Piotroski F 1
- ROE -71.5% · ROA -85.8% · current ratio 12.63
Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.9226 | |
| Change on the day | -7.74% | |
| 52-week range | $0.9226 – $16.60 | |
| Market capitalisation | $20.2M | — |
| Price / earnings (trailing) | -1.27 | |
| Shares traded on the day | 241.1K |
Price & events
Other perspectives
Council score for Aardvark Therapeutics, Inc. Common Stock (AARD): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Englander-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Aardvark Therapeutics, Inc. Common Stock (AARD), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aardvark Therapeutics, Inc. Common Stock (AARD) is listed on NASDAQ. It employs 28 people and is led by Tien-Li Lee. The market values it at $20.2M.
What do the latest results show for Aardvark Therapeutics, Inc. Common Stock (AARD)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
What are the financial strengths and risks for Aardvark Therapeutics, Inc. Common Stock (AARD)?
Short answer
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -4.31 · Piotroski F 1. Trailing ratios: ROE -71.5% · ROA -85.8% · current ratio 12.63.
Data-derived red flags
- Listing risk — at $0.9226 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -4.31 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-71.5%) — the business is not currently generating profit on shareholder capital.
What should you watch next at Aardvark Therapeutics, Inc. Common Stock (AARD)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $300,000 · EPS -3.25 · 9 analysts. Current published price targets run low $1.50 · high $4.00 · consensus $2.40 · median $2.00 against a quoted price of $0.9226 (as of Nov 20, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for AARD.
Checked against the records this page reads, on the dates shown above.
How does Aardvark Therapeutics, Inc. Common Stock compare with its peers?
Short answer
Aardvark Therapeutics, Inc. Common Stock's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| Aardvark Therapeutics, Inc. Common Stock (AARD) — this page | $0.9226 | $20.2M | 30 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $1.50 – $4.00
- Consensus target
- $2.40
- Median target
- $2.00
- Revenue estimate
- $300,000
- EPS estimate
- $-3.25
Consensus record · Captured .
Measured against a quoted price of $0.9226 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 25
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 2
- Other transactions
- 23
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AARD in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AARD in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Aardvark Therapeutics, Inc. Common Stock (AARD)?
- Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
- Aardvark Therapeutics Q3 Cash, Equivalents And Investments $60.3M; Sees Runway Through 2027
- Aardvark Therapeutics Says FDA Meeting Scheduled For Q1 2027 To Discuss ARD-101 Development Plan In Prader-Willi Syndrome; Expects To Resume PWS Clinical Activities In 2027
- Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Common Questions About AARD
These answers are editorial: 1 of these 9 answers is drawn from the AARD research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for AARD?
AARD carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is AARD a good stock to buy?
Stock Expert AI does not rate AARD buy, sell or hold. Aardvark Therapeutics, Inc. Common Stock carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the AARD stock price today?
The last price recorded for Aardvark Therapeutics, Inc. Common Stock (AARD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AARD price target?
The analyst consensus price target for Aardvark Therapeutics, Inc. Common Stock (AARD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for AARD?
The primary risks for Aardvark Therapeutics include clinical trial failures or delays, regulatory hurdles, and competition from other companies developing treatments for metabolic diseases. Limited financial resources and dependence on future funding also pose risks.
What are the key factors to evaluate for AARD?
Aardvark Therapeutics, Inc. Common Stock (AARD) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does AARD data refresh on this page?
AARD's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven AARD's recent stock price performance?
Aardvark Therapeutics, Inc. Common Stock (AARD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AARD overvalued or undervalued right now?
Aardvark Therapeutics, Inc. Common Stock (AARD) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 11 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com